Kymes S. "Can we declare victory and move on?" The case against funding burden-of-disease studies.
PHARMACOECONOMICS 2014;
32:1153-1155. [PMID:
25117204 DOI:
10.1007/s40273-014-0200-8]
[Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Resources devoted to the development of burden-of-disease studies detract from much needed cost-effectiveness and cost-benefit studies. Practitioners need to help funders of burden-of-disease projects recognize the potential of all tools of decision analysis and economic evaluation in improving the efficiency and equity for the health care system.
Collapse